Adult TB Preventive Treatment Dashboard

This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria. Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

| Medicines | WHO Guidelines (LTBI '18) | WHO Guidelines (TPT '20) | EML submitted | EML (2021) | WHO PQ EOI (2021) | WHO PQ Dossier Under Review | WHO PQ listed | Global Fund List of Pharmaceutical Products | Global Fund ERP EOI (Feb 2023) | Global Fund ERP recommended | GDF Catalog |
|-----------------------------------------------|------------------------------|-----------------------------|---------------|------------|-------------------|--------------------------------|---------------|---------------------------------------------------|-----------------------------------|--------------------------------|-------------|
| Isoniazid 300mg tablet/capsule | | | | | | | | | | | |
| Isoniazid/Rifampicin 75/150mg tablet/capsule | | | | | | | | | | | |
| Isoniazid/Rifampicin 150/300mg tablet/capsule | | | | | | | | | | | |
| Rifampicin 150mg capsule | | | | | | | | | | | |
| Rifampicin 300mg capsule | | | | | | | | | | | |
| Rifapentine 150mg tablet | | | | | | | | | | | |
| Rifapentine 300mg | | | | | | | | | | | |

LTBI: Latent TB Infection TPT: TB Preventive Treatment EML: Essential Medicines List

EOI: Expression of Interest ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2023







Status Yes No

N/A

Ineligible for inclusion



Adult TB Preventive Treatment Dashboard

This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

| Medicines | WHO Guidelines (LTBI '18) | WHO Guidelines (TPT '20) | EML submitted | EML (2021) | WHO PQ EOI (2021) | WHO PQ Dossier Under Review | WHO PQ listed | Global Fund List of Pharmaceutical Products | Global Fund ERP EOI (Feb 2023) | Global Fund ERP recommended | GDF Catalog | Status Yes No Ineligible for inclusion N/A |
|------------------------------------------------------------------------------------|------------------------------|-----------------------------|---------------|------------|-------------------|--------------------------------|---------------|---------------------------------------------------|-----------------------------------|--------------------------------|-------------|--------------------------------------------|
| Rifapentine/Isoniazid 300mg/300mg tablet | | | | | | | | | | | | |
| Sulfamethoxazole/Trimethoprim/ Isoniazid/Pyridoxine 800/160/300/ 25mg tablet | | | | | | | | | | | | - |

LTBI: Latent TB Infection

TPT: TB Preventive Treatment

EML: Essential Medicines List

EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2023







